Isemid 1 mg Chewable Tablets for Dogs

The initial/maintenance dose may be temporarily increased when pulmonary oedema
becomes more severe, i.e. reaching alveolar oedema state (see section 4.9).

Issued: October 2024
AN: 02872/2023

Special precautions for use in animals
In dogs presenting with acute pulmonary oedema requiring emergency treatment,
the use of injectable medicinal products should be considered first before
commencing oral diuretic therapy.
Renal function (measurement of blood urea and creatinine as well as urine protein:
creatinine (UPC) ratio), hydration status and serum electrolytes status should be
monitored prior to and during treatment at very regular intervals according to the
benefit-risk assessment performed by the responsible veterinarian (see sections 4.5
and 4.9 of the SPC). The diuretic response to torasemide may increase over time
upon repeated dosing, particularly at doses greater than 0.2 mg/kg/day; therefore
more frequent monitoring should be considered.
Torasemide should be used with caution in cases of diabetes mellitus. Monitoring of
glycaemia in diabetic animals is recommended prior to and during treatment. In dogs
with pre-existing electrolyte and/or water imbalance, this should be corrected prior to
treatment with torasemide.
As torasemide increases thirst, dogs should have free access to fresh water.
In case of loss of appetite and/or vomiting and/or lethargy or in case of treatment
adjustment, renal function (blood urea and creatinine as well as urine
protein:creatinine (UPC) ratio) should be assessed.
In a clinical field trial, the efficacy of Isemid was demonstrated when it was used as a
first line treatment. Transferring treatment from an alternative loop diuretic to this
veterinary medicinal product has not been evaluated and such a change should only
be implemented based on a benefit-risk assessment performed by the responsible
veterinarian.
The safety and efficacy of the product has not been assessed for dogs weighing less
than 2.5 kg. For these animals use only according to the benefit/risk assessment by
the responsible veterinarian.
The tablets are flavoured.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals
This veterinary medicinal product may cause increased urination, thirst and/or
gastrointestinal disturbances and/or hypotension and/or dehydration if ingested. Any
part-used tablets should be returned to the blister pack and then to the original
carton to help prevent access by children. In case of accidental ingestion, particularly
by a child, seek medical advice immediately and show the package leaflet or the
label to the physician.
This veterinary medicinal product may cause hypersensitivity (allergic) reactions in
persons that are sensitized to torasemide. People with known hypersensitivity to
torasemide, to sulfonamides or to any of the excipients should avoid contact with the

Issued: October 2024
AN: 02872/2023
veterinary medicinal product. If symptoms of allergy occur, seek medical advice and
show the product packaging to the physician.
Wash hands after use.
Special precautions for the protection of the environment
Not applicable.
Other precautions
Not applicable.